Navigating Life Sciences M&A Under the Biden Administration | Drug Pricing & Antitrust Considerations

March 25, 2021

Request Recording

Capital Insights.
As the Biden administration transitions into the White House, life sciences companies and investors must navigate new forces on the horizon, including the potential for legal and regulatory action on drug pricing and more aggressive antitrust enforcement.

Please join us for a discussion on recent and probable developments in drug pricing and antitrust emanating from Washington, D.C., their potential impact on life sciences strategic and private equity transactions, and how to anticipate and mitigate their potential impact.